How would you approach a patient who responded to CDK4/6 inhibitor/endocrine therapy combination for metastatic HR+,HER2- breast cancer who now has disease progression which is biopsy proven TNBC?
1 Answers
Mednet Member
Medical Oncology · H Lee Moffitt Cancer Center, University of South Florida
If she has no other distant sites of progression through the cdk4/6, then I would continue this post mastectomy. I would only switch if you have new growing distant mets.
